Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo

Ni, Jie, Cozzi, Paul, Beretov, Julia, Duan, Wei, Bucci, Joseph, Graham, Peter and Li, Yong 2018, Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo, BMC cancer, vol. 18, pp. 1-12, doi: 10.1186/s12885-018-5010-5.

Attached Files
Name Description MIMEType Size Downloads

Title Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo
Author(s) Ni, Jie
Cozzi, Paul
Beretov, Julia
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Bucci, Joseph
Graham, Peter
Li, Yong
Journal name BMC cancer
Volume number 18
Article ID 1092
Start page 1
End page 12
Total pages 12
Publisher BioMed Central
Place of publication London, Eng.
Publication date 2018-11-12
ISSN 1471-2407
Keyword(s) EpCAM
prostate cancer
animal model
PI3K/Akt/mTOR signaling pathway
chemoresistance
radioresistance
Summary BACKGROUND: Development of chemo-/radioresistance is a major challenge for the current prostate cancer (CaP) therapy. We have previously demonstrated that epithelial cell adhesion molecule (EpCAM) is associated with CaP growth and therapeutic resistance in vitro, however, the role of EpCAM in CaP in vivo is not fully elucidated. Here, we aimed to investigate how expression of EpCAM is involved in CaP growth and chemo-/radiotherapy response in NOD/SCID mouse models in vivo and to validate its role as a therapeutic target for CaP therapy. METHODS: EpCAM was knocked down in PC-3 CaP cell line using short hairpin RNA (shRNA). The effect of EpCAM-knockdown (KD) on tumour growth, chemo-/radiotherapy response and animal survival was evaluated on subcutaneous (s.c) and orthotopic mouse models. RESULTS: We found that KD of EpCAM significantly inhibited tumour growth, increased xenograft sensitivity to chemotherapy/radiotherapy, and prolonged the survival of tumour-bearing mice. In addition, we demonstrated that KD of EpCAM is associated with downregulation of the PI3K/Akt/mTOR pathway. CONCLUSIONS: In conclusion, our data confirms that CaP growth and chemo-/radioresistance in vivo is associated with over-expression of EpCAM, which serves both a functional biomarker and promising therapeutic target.
Language eng
DOI 10.1186/s12885-018-5010-5
Field of Research 1112 Oncology And Carcinogenesis
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, The Authors
Persistent URL http://hdl.handle.net/10536/DRO/DU:30115695

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Checking
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 73 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 27 Nov 2018, 09:32:47 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.